ARMP Armata Pharmaceuticals Inc.

3.69
-0.06  -2%
Previous Close 3.75
Open 3.58
Price To Book 2.05
Market Cap 68,798,917
Shares 18,644,693
Volume 5,069
Short Ratio 1.88
Av. Daily Volume 16,859
Stock charts supplied by TradingView

NewsSee all news

  1. Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

    MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted

  2. Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector

    MARINA DEL REY, Calif., April 28, 2020 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

  3. Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

    MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

  4. Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update

    MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted

  5. Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation

    MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Trials to be initiated in 2020.
AP-PA02
Cystic fibrosis

Latest News

  1. Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

    MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted

  2. Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector

    MARINA DEL REY, Calif., April 28, 2020 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

  3. Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

    MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

  4. Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update

    MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted

  5. Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation

    MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for

  6. Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

    MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics

  7. Innoviva Reports Fourth Quarter 2019 Financial Results

    Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9% to $70.3 million in the fourth quarter of 2019,

  8. Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs

    MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for

  9. Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

    MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted

  10. Armata Pharmaceuticals Issues Letter to Shareholders

    MARINA DEL REY, Calif., Oct. 31, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for

  11. Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

    MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for

  12. Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.

    MARINA DEL REY, Calif., Oct. 10, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for

  13. Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference

    MARINA DEL REY, Calif., Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant

  14. Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

    MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted